In tests of its leukemia-fighting drug, Juno Therapeutics, Inc., botched the handling of patient deaths — and even how many, Judy Phair observes. Incomplete information, dribbled out as the crisis unfolded, put the firm on the defense. It’s the latest the in Wall Street Journal’s Risk & Compliance Journal.
Whether it's global communications, branding or strategic planning - it's all about you
Boards’ Failing Oversight: How Does It Happen?
